Show simple item record

dc.contributor.authorCyll, Karolina Urszula
dc.contributor.authorHaug, Erik Skaaheim
dc.contributor.authorPradhan, Manohar
dc.contributor.authorVlatkovic, Ljijana
dc.contributor.authorCarlsen, Birgitte
dc.contributor.authorLöffeler, Sven
dc.contributor.authorKildal, Wanja
dc.contributor.authorSkogstad, Karin
dc.contributor.authorTorkelsen, Frida Hauge
dc.contributor.authorSyvertsen, Rolf Anders
dc.contributor.authorAskautrud, Hanne Arenberg
dc.contributor.authorLiestøl, Knut
dc.contributor.authorKleppe, Andreas
dc.contributor.authorDanielsen, Håvard Emil Greger
dc.date.accessioned2024-09-25T11:42:41Z
dc.date.available2024-09-25T11:42:41Z
dc.date.issued2024-07-03
dc.description.abstractBackground: Current risk stratification tools for prostate cancer patients under active surveillance (AS) may inadequately identify those needing treatment. We investigated DNA ploidy and PTEN as potential biomarkers to predict aggressive disease in AS patients.<p><p> Methods: We assessed DNA ploidy by image cytometry and PTEN protein expression by immunohistochemistry in 3197 tumour-containing tissue blocks from 558 patients followed in AS at a Norwegian local hospital. The primary endpoint was treatment, with treatment failure (biochemical recurrence or initiation of salvage therapy) as the secondary endpoint. <p>Results: The combined DNA ploidy and PTEN (DPP) status at diagnosis was associated with treatment-free survival in univariable- and multivariable analysis, with a HR for DPP-aberrant vs. DPP-normal tumours of 2.12 (p < 0.0001) and 1.94 (p < 0.0001), respectively. Integration of DNA ploidy and PTEN status with the Cancer of the Prostate Risk Assessment (CAPRA) score improved risk stratification (c-index difference = 0.025; p = 0.0033). Among the treated patients, those with DPP-aberrant tumours exhibited a significantly higher likelihood of treatment failure (HR 2.01; p = 0.027). <p>Conclusions: DNA ploidy and PTEN could serve as additional biomarkers to identify AS patients at increased risk of developing aggressive disease, enabling earlier intervention for nearly 50% of the patients that will eventually receive treatment with current protocol.en_US
dc.identifier.citationCyll K, Haug ES, Pradhan M, Vlatkovic L, Carlsen B, Löffeler S, Kildal W, Skogstad K, Torkelsen, Syvertsen RA, Askautrud HA, Liestøl K, Kleppe A, Danielsen HE. DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance. British Journal of Cancer. 2024
dc.identifier.cristinIDFRIDAID 2282878
dc.identifier.doi10.1038/s41416-024-02780-x
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.urihttps://hdl.handle.net/10037/34865
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalBritish Journal of Cancer
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleDNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillanceen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)